Literature DB >> 10821410

Sensitive high-performance liquid chromatographic method for the determination of the lactone form and the lactone plus hydroxy-acid forms of the new camptothecin derivative DX-8951 in human plasma using fluorescence detection.

T Oguma1, Y Ohshima, M Nakaoka.   

Abstract

A sensitive quantitation of the lactone form and the lactone plus hydroxy-acid forms of DX-8951, a camptothecin derivative, in human plasma has been investigated by high-performance liquid chromatography (HPLC). This assay method consisted of two analytical procedures. In Procedure I, the lactone form was collected by the stepwise separation on a C18 cartridge. In Procedure II, the lactone plus hydroxy-acid forms were collected using another batch of the plasma sample by co-elution of the two forms from a C18 cartridge with acidic solution. The hydroxy-acid form of DX-8951 was quantitated from the difference of the lactone plus hydroxy-acid forms and the lactone form. Thereafter, these pre-treated samples were assayed by HPLC under the same HPLC conditions with a spectrofluorometer and a reverse-phase ODS column. The mobile phase was acetonitrile/0.05 M potassium dihydrogen phosphate (pH 3) (18:82, v/v) at a flow-rate of 1.0 ml/min. For the assay of the lactone form and the lactone plus hydroxy-acid forms of DX-8951 in plasma, analytical method were validated over the range 0.2-50 ng/ml.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10821410     DOI: 10.1016/s0378-4347(00)00108-0

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  2 in total

1.  A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer.

Authors:  Jaffer A Ajani; Chris Takimoto; Carlos R Becerra; Alejandro Silva; Luis Baez; Allen Cohn; Pierre Major; Makio Kamida; Kevie Feit; Robert De Jager
Journal:  Invest New Drugs       Date:  2005-10       Impact factor: 3.850

2.  A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic adenocarcinoma of the colon or rectum.

Authors:  Melanie E Royce; Eric K Rowinsky; Paulo M Hoff; John Coyle; Robert DeJager; Richard Pazdur; Leonard B Saltz
Journal:  Invest New Drugs       Date:  2004-01       Impact factor: 3.850

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.